Pharmacokinetics of antifungal medications are considered inherently more unpredictable than most antibacterials.

This project will link our international collaborators to generate new knowledge on the adequacy of current antifungal dosing (caspofungin, micafungin, anidulafungin, voriconazole, itraconazole, posaconazole, fluconazole) in a large cohort of ICU patients from over a 6-month patient enrolment period.

Project members

Professor Jason Roberts

Chief Investigator and CRE lead

Professor Monica Slavin

Chief Investigator

Professor Jeffrey Lipman

Chief Investigator

Professor Jan De Waele

Chief Investigator

Professor Jean-Yves Lefrant

Associate Investigator

Professor Jordi Rello

Associate Investigator

Dr Despoina Koulenti

Associate Investigator